These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22563098)

  • 1. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.
    Prochaska JJ; Hilton JF
    BMJ; 2012 May; 344():e2856. PubMed ID: 22563098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.
    Singh S; Loke YK; Spangler JG; Furberg CD
    CMAJ; 2011 Sep; 183(12):1359-66. PubMed ID: 21727225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
    Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
    Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sterling LH; Windle SB; Filion KB; Touma L; Eisenberg MJ
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26903004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
    Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
    Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
    Cahill K; Stevens S; Perera R; Lancaster T
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD009329. PubMed ID: 23728690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial.
    Fagerström K; Gilljam H; Metcalfe M; Tonstad S; Messig M
    BMJ; 2010 Dec; 341():c6549. PubMed ID: 21134997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.
    Svanström H; Pasternak B; Hviid A
    BMJ; 2012 Nov; 345():e7176. PubMed ID: 23138033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Maggo S; Tan M; Savage R; Ashton J
    Drug Saf; 2012 Jan; 35(1):33-43. PubMed ID: 22149418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.
    Thomas KH; Martin RM; Knipe DW; Higgins JP; Gunnell D
    BMJ; 2015 Mar; 350():h1109. PubMed ID: 25767129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study.
    Graham DJ; By K; McKean S; Mosholder A; Kornegay C; Racoosin JA; Young J; Levenson M; MaCurdy TE; Worrall C; Kelman JA
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1205-12. PubMed ID: 25044169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
    Tonstad S; Davies S; Flammer M; Russ C; Hughes J
    Drug Saf; 2010 Apr; 33(4):289-301. PubMed ID: 20297861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varenicline's adverse events. Choice of summary statistics: relative and absolute measures.
    Prochaska JJ; Hilton JF
    BMJ; 2013 Feb; 346():f1092. PubMed ID: 23444433
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of varenicline in patients with cardiovascular disease.
    Haber SL; Boomershine V; Raney E
    J Pharm Pract; 2014 Feb; 27(1):65-70. PubMed ID: 24080536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.